Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Clinical Diabetes
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Spectrum

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Clinical Diabetes
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Spectrum
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
Pharmacy and Therapeutics

Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide

  1. Elizabeth B. Hearn and
  2. Justin J. Sherman
  1. University of Mississippi School of Pharmacy, Jackson, MS
  1. Corresponding author: Elizabeth B. Hearn, elizabethbellhearn{at}gmail.com
Diabetes Spectrum 2021 Jan; 34(1): 73-75. https://doi.org/10.2337/ds20-0033
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Glucagon-like peptide 1 (GLP-1) receptor agonists are a safe and effective treatment option for patients with type 2 diabetes (1). Selective activation of the GLP-1 receptor causes glucose-dependent insulin secretion, resulting in a very low risk of hypoglycemia (2). The additional mechanism of slowing gastric emptying has resulted in reliable weight loss with this class of antihyperglycemic medications (3). In addition, multiple agents in this drug class (semaglutide, liraglutide, and dulaglutide) have been proven to reduce the risk of cardiovascular events (4).

Furthermore, the possibility of once-weekly dosing for glycemic control in type 2 diabetes has been realized with some GLP-1 receptor agonists (semaglutide, exenatide extended-release, and dulaglutide) as a result of albumin binding that decreases renal clearance and protects against metabolic degradation by the dipeptidyl peptidase-4 enzyme (2). Poor adherence to pharmacologic therapy is well documented in patients with type 2 diabetes and is linked to inadequate glycemic control (based on the American Diabetes Association’s general A1C goal of <7%), and once-weekly dosing has been shown to improve adherence rates (5,6).

The use of GLP-1 receptor agonists in practice has become more prominent in recent years, and adverse reactions are generally benign. Most commonly, patients have reported gastrointestinal upset (>10%) and injection-site reactions (>1%) (1,7).

General injection-site reactions (e.g., erythema, pain, or rash) have been reported with all of the commercially available GLP-1 receptor agonists (i.e., exenatide, lixisenatide, liraglutide, dulaglutide, and semaglutide) (8–13). However, post-marketing reports have revealed that exenatide extended-release, specifically, may cause more alarming injection-site …

View Full Text

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
Diabetes Spectrum: 34 (1)

In this Issue

January 2021, 34(1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Spectrum.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide
(Your Name) has forwarded a page to you from Diabetes Spectrum
(Your Name) thought you would like to see this page from the Diabetes Spectrum web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide
Elizabeth B. Hearn, Justin J. Sherman
Diabetes Spectrum Jan 2021, 34 (1) 73-75; DOI: 10.2337/ds20-0033

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide
Elizabeth B. Hearn, Justin J. Sherman
Diabetes Spectrum Jan 2021, 34 (1) 73-75; DOI: 10.2337/ds20-0033
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Case Presentation
    • Discussion
    • Conclusion
    • Article Information
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Safety and Efficacy of Dietary Supplements for Diabetes
  • Cannabidiol (CBD) Use in Type 2 Diabetes: A Case Report
Show more Pharmacy and Therapeutics

Similar Articles

Navigate

  • Current Issue
  • Papers in Press
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Diabetes Care
  • Clinical Diabetes
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Spectrum Print ISSN: 1040-9165, Online ISSN: 1944-7353.